Benzbromarone is a uricosuric agent and weak non-competitive inhibitor of xanthine oxidase used in the treatment of gout. It is a brominated analogue of withdrawn uricosuric benziodarone and benzarone, and is structurally related to the antiarrhythmic amiodarone.
via PubMed
Benzbromarone is a uricosuric agent and weak non-competitive inhibitor of xanthine oxidase used in the treatment of gout. It is a brominated analogue of withdrawn uricosuric benziodarone and benzarone, and is structurally related to the antiarrhythmic amiodarone.
Benzbromarone was withdrawn from most European countries in 2003 due to the risk of idiosyncratic hepatotoxicity, but remains heavily used in Asia and South America. Despite this risk, it is generally considered highly effective and well tolerated in most patients. Clinical trials dating back to 1981 and as recent as 2022, as well as meta-analyses, have reported its superior efficacy compared to both non-uricosuric xanthine oxidase inhibitors (allopurinol and febuxostat) and another uricosuric drug, probenecid.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).